June 1, 2021 7:42am
The only change is the date as Q2 whittles it way down
News: Alnylam Pharmaceuticals (ALNY) has achieved full patient enrollment in its APOLLO-B P3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (ATTR) amyloidosis. Enrollment was completed with over 300 ATTR amyloidosis patients across 90 sites in more than 20 countries
Pre-open indications: 7 BUYs and 1 SELL
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are UP +0.65% (+224 points), S&P futures are UP +0.52% (+22 points) and NASDAQ futures are UP +0.39% (+54 points)
U.S. stock futures are up in the pre-market, on Tuesday,
European markets moved higher after closing out their fourth straight month of gains,
Asia-Pacific markets were mostly higher as investors reacted to China’s Caixin/Markit manufacturing Purchasing Managers’ Index (PMI) for May.
Data Docket: China’s Caixin/Markit manufacturing Purchasing Managers’ Index (PMI) for May’s final activity reading came in at 52, slightly exceeding analyst expectations of 51.9. IHS Markit manufacturing PMI readings for May showed activity in the euro zone hitting a record high 63.1, up from 62.9 in April and exceeding an initial flash estimate of 62.8. In the U.K., factory activity rose to 65.6 in May from 60.9 in April, its sharpest increase since records began, as a windfall of new orders drove the country’s industrial resurgence.
Henry’omics:
Back from the Memorial Day holiday weekend …
the Dow was up +1.93% and the S&P 500 gained 0.55% while the Nasdaq lost -1.53% in May. The small-cap Russell 2000 rose 0.11% in May to post its eighth positive month in a row — its longest monthly win streak since 1995.
However, the Nasdaq gained 2.06% last week to post its best weekly performance since April.
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (31) to date … https://www.regmedinvestors.com/articles/11628
Friday’s evening’s recap: “wrapping the week on a weak note; while only some of the oversold were on the receiving end with share pricing growth.”
- The Nasdaq closed UP +12.46 points (+0.09%);
- The IBB closed up +0.78% and XBI closed down -0.38%
- Sector volume was LOW with 0 of the 13-upside having higher than the 3-month average volume with the volume of 3 of 19-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +0.02 points or +0.12% at 16.76
- Friday’s percentage (%) of the 13-upside were +0.06% (RGNX) to +4.46% (NTLA) while the 19-downside ranges from -019% (CRSP) to -15.55% (BSTG);
Q2/21:
June: begins today
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) - Maintaining Sell
Biostage (BSTG) closed down -$0.20 to $1.12 with 4.372 shares traded after Thursday’s flat at $1.30 after being down -$0.21 to $1.11 with 5617 shares traded (the “pump and promote” was back), Wednesdays at $1.30 again with 45 shares traded and last Tuesday’s flat with 358 shares traded, Monday’s flat with 45 shares traded.
Question#1: WHERE is the next level of funding coming from, is it further warrant execution cash generation for funding? Should its “runway” be considered extremely short or even non-existent?
Question#2: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?
MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
SELL:
Precigen (PGEN) closed down -$0.24 to $6.60 and has a negative -$0.15 or -2.27% aftermarket indication from Friday.
BUY:
Alnylam Pharmaceuticals (ALNY) closed up +$1.76 to $141.99 with NO pre-market indication.
bluebird bio (BLUE) closed down-$0.60 to $31.12 and has a positive +$028 or +0.90% aftermarket indication from Friday.
Cellectis SA (CLLS) closed up +$0.26 to $15.67 and has a positive +$0.17 or +$1.08% pre-market indication.
CRISPR Therapeutics (CRSP) closed down -$0.22 to $118.18 and has a positive +$0.82 or +0.69% pre-market indication.
Editas Medicine (EDIT) closed down -$0.64 to $33.95 and has a positive +$0.55 or +1.62% pre-market indication.
Ionis Pharmaceuticals (IONS) closed UP +$0.40 to $37.25 and has a positive +$0.75 or +2.01% aftermarket indication from Friday.
Sage Therapeutics (SAGE) closed -$2.16to $69.60 and has a positive +$2.40 or +3.45% after market indication from Friday.
The BOTTOM LINE: New highs are “in store” in the hype of a new month and the reopening status of the economy as constraints come-off many states and some companies re-open their doors to employees.
I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).
My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
